Pre-Diagnostic Circulating Resistin Concentrations Are Not Associated with Colorectal Cancer Risk in the European Prospective Investigation into Cancer and Nutrition Study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Pre-Diagnostic Circulating Resistin Concentrations Are Not Associated with Colorectal Cancer Risk in the European Prospective Investigation into Cancer and Nutrition Study. / Thu-Thi Pham; Nimptsch, Katharina; Aleksandrova, Krasimira; Jenab, Mazda; Reichmann, Robin; Wu, Kana; Tjonneland, Anne; Kyro, Cecilie; Schulze, Matthias B.; Kaaks, Rudolf; Katzke, Verena; Palli, Domenico; Pasanisi, Fabrizio; Ricceri, Fulvio; Tumino, Rosario; Krogh, Vittorio; Roodhart, Jeanine; Castilla, Jesus; Sanchez, Maria-Jose; Colorado-Yohar, Sandra Milena; Harbs, Justin; Rutegard, Martin; Papier, Keren; Aglago, Elom K.; Dimou, Niki; Mayen-Chacon, Ana-Lucia; Weiderpass, Elisabete; Pischon, Tobias.
I: Cancers, Bind 14, Nr. 22, 5499, 2022.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Pre-Diagnostic Circulating Resistin Concentrations Are Not Associated with Colorectal Cancer Risk in the European Prospective Investigation into Cancer and Nutrition Study
AU - Thu-Thi Pham, null
AU - Nimptsch, Katharina
AU - Aleksandrova, Krasimira
AU - Jenab, Mazda
AU - Reichmann, Robin
AU - Wu, Kana
AU - Tjonneland, Anne
AU - Kyro, Cecilie
AU - Schulze, Matthias B.
AU - Kaaks, Rudolf
AU - Katzke, Verena
AU - Palli, Domenico
AU - Pasanisi, Fabrizio
AU - Ricceri, Fulvio
AU - Tumino, Rosario
AU - Krogh, Vittorio
AU - Roodhart, Jeanine
AU - Castilla, Jesus
AU - Sanchez, Maria-Jose
AU - Colorado-Yohar, Sandra Milena
AU - Harbs, Justin
AU - Rutegard, Martin
AU - Papier, Keren
AU - Aglago, Elom K.
AU - Dimou, Niki
AU - Mayen-Chacon, Ana-Lucia
AU - Weiderpass, Elisabete
AU - Pischon, Tobias
PY - 2022
Y1 - 2022
N2 - Simple Summary Resistin has been proposed to link to cancer development via inflammatory processes. Prior case-control studies suggest higher post-diagnosis resistin concentrations in CRC cases compared to controls. Here, we found no association between pre-diagnostic circulating resistin concentrations and the risk of CRC; however, we observed a marginally significant association among cases (and their matched controls) diagnosed with CRC within the first two years of follow-up, whereas no such association was observed among cases (and their matched controls) diagnosed with CRC after two years of follow-up. We speculate that resistin is more likely a marker of existing tumors than a risk factor of CRC. Resistin is a polypeptide implicated in inflammatory processes, and as such could be linked to colorectal carcinogenesis. In case-control studies, higher resistin levels have been found in colorectal cancer (CRC) patients compared to healthy individuals. However, evidence for the association between pre-diagnostic resistin and CRC risk is scarce. We investigated pre-diagnostic resistin concentrations and CRC risk within the European Prospective Investigation into Cancer and Nutrition using a nested case-control study among 1293 incident CRC-diagnosed cases and 1293 incidence density-matched controls. Conditional logistic regression models controlled for matching factors (age, sex, study center, fasting status, and women-related factors in women) and potential confounders (education, dietary and lifestyle factors, body mass index (BMI), BMI-adjusted waist circumference residuals) were used to estimate relative risks (RRs) and 95% confidence intervals (CIs) for CRC. Higher circulating resistin concentrations were not associated with CRC (RR per doubling resistin, 1.11; 95% CI 0.94-1.30; p = 0.22). There were also no associations with CRC subgroups defined by tumor subsite or sex. However, resistin was marginally associated with a higher CRC risk among participants followed-up maximally two years, but not among those followed-up after more than two years. We observed no substantial correlation between baseline circulating resistin concentrations and adiposity measures (BMI, waist circumference), adipokines (adiponectin, leptin), or metabolic and inflammatory biomarkers (C-reactive protein, C-peptide, high-density lipoprotein cholesterol, reactive oxygen metabolites) among controls. In this large-scale prospective cohort, there was little evidence of an association between baseline circulating resistin concentrations and CRC risk in European men and women.
AB - Simple Summary Resistin has been proposed to link to cancer development via inflammatory processes. Prior case-control studies suggest higher post-diagnosis resistin concentrations in CRC cases compared to controls. Here, we found no association between pre-diagnostic circulating resistin concentrations and the risk of CRC; however, we observed a marginally significant association among cases (and their matched controls) diagnosed with CRC within the first two years of follow-up, whereas no such association was observed among cases (and their matched controls) diagnosed with CRC after two years of follow-up. We speculate that resistin is more likely a marker of existing tumors than a risk factor of CRC. Resistin is a polypeptide implicated in inflammatory processes, and as such could be linked to colorectal carcinogenesis. In case-control studies, higher resistin levels have been found in colorectal cancer (CRC) patients compared to healthy individuals. However, evidence for the association between pre-diagnostic resistin and CRC risk is scarce. We investigated pre-diagnostic resistin concentrations and CRC risk within the European Prospective Investigation into Cancer and Nutrition using a nested case-control study among 1293 incident CRC-diagnosed cases and 1293 incidence density-matched controls. Conditional logistic regression models controlled for matching factors (age, sex, study center, fasting status, and women-related factors in women) and potential confounders (education, dietary and lifestyle factors, body mass index (BMI), BMI-adjusted waist circumference residuals) were used to estimate relative risks (RRs) and 95% confidence intervals (CIs) for CRC. Higher circulating resistin concentrations were not associated with CRC (RR per doubling resistin, 1.11; 95% CI 0.94-1.30; p = 0.22). There were also no associations with CRC subgroups defined by tumor subsite or sex. However, resistin was marginally associated with a higher CRC risk among participants followed-up maximally two years, but not among those followed-up after more than two years. We observed no substantial correlation between baseline circulating resistin concentrations and adiposity measures (BMI, waist circumference), adipokines (adiponectin, leptin), or metabolic and inflammatory biomarkers (C-reactive protein, C-peptide, high-density lipoprotein cholesterol, reactive oxygen metabolites) among controls. In this large-scale prospective cohort, there was little evidence of an association between baseline circulating resistin concentrations and CRC risk in European men and women.
KW - pre-diagnostic resistin
KW - colorectal cancer
KW - risk
KW - prospective
KW - inflammation
KW - MOLECULAR-WEIGHT ADIPONECTIN
KW - C-REACTIVE PROTEIN
KW - INSULIN-RESISTANCE
KW - OBESITY
KW - BIOMARKERS
KW - INFLAMMATION
KW - EXPRESSION
KW - ADIPOKINES
KW - VALIDITY
KW - RECEPTOR
U2 - 10.3390/cancers14225499
DO - 10.3390/cancers14225499
M3 - Journal article
C2 - 36428592
VL - 14
JO - Cancers
JF - Cancers
SN - 2072-6694
IS - 22
M1 - 5499
ER -
ID: 328226121